CellaVision ABCVLLY +12.06%69 PB Ratio is 3.43 as of Jun. 24, 2026, which is 76% below its 10-year median of 14.19. GuruFocus rates CVLLY with a GF Score™ of 69/100 and a GF Value™ of $12.48 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 787 Medical Devices & Instruments companies, CellaVision AB ranks worse than 71.03% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-24), CellaVision AB's share price is $7.06. CellaVision AB's Book Value per Share for the quarter that ended in Mar. 2026 was $2.06. Hence, CellaVision AB's PB Ratio of today is 3.43.
The historical rank and industry rank for CellaVision AB's PB Ratio or its related term are showing as below:
CVLLY'
s PB Ratio Range Over the Past 10 Years
Min: 3.09 Med: 14.19 Max: 29.63
Current: 3.57
During the past 13 years, CellaVision AB's highest PB Ratio was 29.63. The lowest was 3.09. And the median was 14.19.
CVLLY's PB Ratio is ranked worse than 71.03% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.04
vs CVLLY: 3.57
During the past 12 months, CellaVision AB's average Book Value Per Share Growth Rate was 9.00% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 11.40% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 15.20% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 18.50% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of CellaVision AB was 78.10% per year. The lowest was 5.30% per year. And the median was 17.70% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
CellaVision AB PB Ratio Related Terms
CellaVision AB PB Ratio Historical Data
* Premium members only.
The historical data trend for CellaVision AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, CellaVision AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CellaVision AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, CellaVision AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where CellaVision AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
CellaVision AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
CellaVision AB (CVLLY) has a PB Ratio of 3.43 as of Jun. 24, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CellaVision AB and its competitors. This is 76% below median its historical median of 14.19. Over the past decade, CellaVision AB's PB Ratio has ranged from 3.09 to 29.63. According to the industry distribution chart, CellaVision AB ranks #559 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 71%.
Is CellaVision AB's PB Ratio too high?
CellaVision AB's current PB Ratio of 3.43 is 76% below median its 10-year median of 14.19. Over the past 10 years, this metric has ranged from a low of 3.09 to a high of 29.63. The Medical Devices & Instruments industry median PB Ratio is 2.04. CellaVision AB's value of 3.43 is 68.1% above this industry median. Based on the distribution chart, CellaVision AB ranks #559 out of 787 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, CellaVision AB has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does CellaVision AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, CellaVision AB ranks #559 out of 787 companies for PB Ratio. This places CellaVision AB in the lower half of its industry. The industry median PB Ratio is 2.04. CellaVision AB's value of 3.43 is 68.1% above this benchmark. Historically, CellaVision AB's own PB Ratio has ranged from 3.09 to 29.63 over the past decade. While the company's 10-year median is 14.19 vs. the industry median of 2.04, CellaVision AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.04, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CellaVision AB's current PB Ratio of 3.43 is 68.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on CellaVision AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CellaVision AB's current PB Ratio is 3.43, which is 76% below median its own 10-year median of 14.19. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CellaVision AB stock overvalued right now?
Based on GuruFocus' analysis, CellaVision AB (CVLLY) is currently considered Significantly Undervalued. The stock's GF Value™ is $12.48, compared to a current price of $7.06 — trading 43.4% below its estimated fair value. The current PB Ratio is 3.43, which is 76% below median its 10-year median of 14.19 and 68.1% above the Medical Devices & Instruments industry median of 2.04. CellaVision AB's overall GF Score™ is 69/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For CellaVision AB (CVLLY), the current PB Ratio is 3.43 as of Jun. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CellaVision AB (CVLLY) Overvalued in 2026?
Based on GuruFocus' analysis, CellaVision AB stock appears to be undervalued.
The current stock price of $7.06 is trading 43.4% below its estimated GF Value™ of $12.48.
GuruFocus considers CellaVision AB to be Significantly Undervalued.
Key valuation signals for CVLLY:
PB Ratio: 3.43 (76% below median its 10-year median of 14.19)
GF Value™: $12.48 vs. price of $7.06 (43.4% below fair value)
Industry Position: 68.1% above the Medical Devices & Instruments median (#559 of 787)
No single metric tells the full story. See the CVLLY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CellaVision AB is engaged in developing and selling instruments, software, and reagents for blood and body fluid analysis. The company automates parts of the sample preparation process and replaces manual microscopes with instruments based on digital image analysis technology and artificial intelligence. The solutions contribute to more effective workflows and higher quality in laboratory medicine. The product offer consists of products and solutions for standardized laboratory diagnostics and improved performance for cellular image processing and systems for digital microscopy in hematology, consisting of reagents, instruments, and supplementary software and peripheral equipment.
69GF Score
Get the complete analysis for CVLLY
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CVLLY has been successfully added to your 
